Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jun 13, 2024 8:54pm
85 Views
Post# 36088353

Global Joint Venture or Partnership

Global Joint Venture or Partnership

Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”

Gilles Gagnon, Chief Executive Officer of the Company, said: “with the shared benefits, additional competencies and resources resulting from this merger, we are now poised to push forward exciting development programs..."

With an optimized structure with additional competencies and resources, and access to NASDAQ could we see a strategic partnership between a major player and AEZS for PGX/immune booster, and PGX/CoQ10, etc., to address the global market? The 50L scale was expected to provide materials for potential partners previously. The decision point for mass industrialization could be commissioned in Q3. The PGX/immune booster plant alone previously had an estimated $100 million net present value but what if AEZS went global in a major deal. We could see a deal for much more than just an immune booster. 

---------

CZO October 2022 news release:

Knowing that Ceapro’s PGX-processed carriers can deliver CoQ10 into the tissues,
we will advance to the next stage which includes looking for efficacy of these new chemical entities along with a partner involved in the marketing and sales of various forms of delivery systems that can be included in food, drinks, cream formulations, medical supplies like thin films, skin patches and up to nutraceuticals and pharmaceuticals,” said Gilles Gagnon, M.Sc., MBA, President and CEO. 

-------------


Joint Venture or Partnership

AEZS could form a joint venture or strategic partnership with a larger company to co-develop and commercialize the PGX platform. This would provide funding, expertise and resources to accelerate development and commercialization, while allowing AEZS to retain partial ownership and share in future revenues

---------


If AEZS is seen as having the emerging gold standard it could also go for gold standard market share with a gold standard partner on a global scale. Ronnie Miller helped pioneer global operating models and he is "thrilled" with the merger and its transformational products.

<< Previous
Bullboard Posts
Next >>